Results

CRUZIVAX publication

Lee S., Nasr S., Rasheed S., Liu Y., Hartwig O., Kaya C., Boese A., Koch M., Herrmann J., Müller R., Loretz B., Buhler E., ... , Hirsch A.K.H., Lehr C.M. (2022)
Proteoid biodynamers for safe mRNA transfection via pH-responsive nanorods enabling endosomal escape
J.Control.Release, 353
DOI: 10.1016/j.jconrel.2022.12.018 HZI-Repositorium PubMed

This study aims to inform the development of two vaccines for the prevention and treatment of Trypanosoma cruzi infection, and guide their pre-clinical phase up to clinical phase I. The three main objectives are: 1) to explore patients’ and policy makers’ preferences on the candidate vaccines in Argentina and Spain; 2) to investigate health-related quality of life of patients affected by Chagas disease; and 3) to assess the potential health provider savings associated with the vaccines, in terms of resource use and health care costs.

CRUZIVAX public deliverables

  • D16.1: A PowerPoint presentation of the project
    pdf (1.80 MB)
  • D16.2: A PowerPoint presentation of the Cruzivax project website
    pdf (4.36 MB)

When available, further results will be made public here and on our Zenodo Community.
https://zenodo.org/communities/cruzivax/